Oramed Letter to Shareholders
Provided By PR Newswire
Last update: Jun 26, 2024
NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.
Read more at prnewswire.com2
-0.09 (-4.31%)
Find more stocks in the Stock Screener
ORMP Latest News and Analysis
19 days ago - ChartmillUnusual volume stocks in Wednesday's sessionDiscover the stocks with unexpected trading volume in today's session on the US markets.
20 days ago - ChartmillWhat's going on in today's sessionKeep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
